Besides these, IFN-α also exerts immunomodulatory effects such as up-regulation of MHC class I, enhancement of maturation and activation of dendritic cells, thus cross-priming CD8+ T cell response, which make it an appropriate candidate to combine with cancer vaccines [11, 12]. This evidence concerns the gene IFNA17 and cancer.